G Protein-Coupled Receptor-Targeting Antibody-Drug Conjugates: Current Status and Future Directions

Authors

Peyton High
Kendra S Carmon

Publication Date

6-28-2023

Journal

Cancer Letters

Abstract

In recent years, antibody-drug conjugates (ADCs) have emerged as promising anti-cancer therapeutic agents with several having already received market approval for the treatment of solid tumor and hematological malignancies. As ADC technology continues to improve and the range of indications treatable by ADCs increases, the repertoire of target antigens has expanded and will undoubtedly continue to grow. G protein-coupled receptors (GPCRs) are well-characterized therapeutic targets implicated in many human pathologies, including cancer, and represent a promising emerging target of ADCs. In this review, we will discuss the past and present therapeutic targeting of GPCRs and describe ADCs as therapeutic modalities. Moreover, we will summarize the status of existing preclinical and clinical GPCR-targeted ADCs and address the potential of GPCRs as novel targets for future ADC development.

Keywords

Humans, Immunoconjugates, Antineoplastic Agents, Neoplasms, Hematologic Neoplasms, antibody, drug conjugate, G protein-coupled receptor, linker, payload

Comments

PMID: 37100113